The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
Through the deal, Helomics aims to build a predictive model of prostate cancer drug response based on a combination of genomic and spectroscopy data.
The companies will use their respective technologies in a study investigating the associations between ovarian cancer and the gut microbiome.
Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.
Helomics' managing executives will remain to manage TumorGenesis, Precision's newly formed subsidiary for cancer diagnostics and therapy.
The assay is based on Ariel's Smart-MD bioinformatics platform, which combines patient symptoms and history with next-generation sequencing data.
The companies partnered last month to develop new personalized cancer diagnostics using the Helomics D-Chip bioinformatics platform.
Skyline will use Helomics' D-Chip bioinformatics repository of more than 149,000 tumors to develop cancer diagnostics.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.